Table 1: Strategies for the induction of anti-MUC1 T cell responses that are being studied in vitro and in vivo.

AuthorStrategyCancer ModelEffect

Deguchi et al. [43] -gal epitope to increase immunogenicity of MUC1Pancreatic cancer mouse modelAntibody induction, mouse tumor regression, induction of T cell responses
Kovjazin et al. [44]ImMucin peptide 21merMouse/PBMC of patientsCD4+ and CD8+ T lymphocyte responses in vitro and in vivo
Choi et al. [45]DNA vaccine (MUC1/HSP70)B16 micecytotoxic T cell response induction/ tumor growth inhibition
Chen et al. [46]MUC1 mRNA, dendritic cell transfectionPancreatic cancerMUC1 mRNA-transfected dendritic cells can induce MUC1-specific CD8+ T cell responses
Wright et al. [47]MUC1 peptide with substitution of O-glycosylation siteHuman adenocarcinomaO-glycosylation site substitution improves immunogenicity
Kobukai et al. [48]MPA11P vehicle of a 30mer MUC1 peptideMouseReduction of tumor size, lymphocyte infiltration
Lakshmiarayanan et al. [49]Tripartite MUC1 vaccine (TLR2, Thelpher, MUC1 glycopeptides)Mouse model of mammary cancerIgG antibodies, cytotoxic T lymphocytes, activation of innate immune response
Sugiura et al. [50]MUC1 DNA vaccineMouse/colonInduction of CD4+ T cell responses, not CD8+
Ryan et al. [39, 40]TN MUC1 glycopeptideMouseT cell responses against glycosylated peptides, but not unglycosylated peptides
Choi et al. [51]MUC1 DNA vaccination, enhanced by mANT2 shRNAMouse melanomaCombination enhanced effects of DNA vaccination, MUC1 CD8+ T cell responses
Jeon et al. [52]DNA vaccinationMouseTumor growth inhibition, CD8+ IFN- increased